Research
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
BMJ 2006; doi: https://doi.org/10.1136/bmj.38793.468449.AE (Published 24 April 2006) Cite this as: BMJ 2006;:bmj;bmj.38793.468449.AEv2Related articles
- Education And Debate Published: 05 June 1999; BMJ 318 doi:10.1136/bmj.318.7197.1548
- Paper Published: 26 June 2003; BMJ 326 doi:10.1136/bmj.326.7404.1423
- Paper Published: 05 February 1994; BMJ 308 doi:10.1136/bmj.308.6925.367
- Editorial Published: 11 May 2006; BMJ 332 doi:10.1136/bmj.332.7550.1103
- Letter Published: 25 May 2006; BMJ 332 doi:10.1136/bmj.332.7552.1272-a
- Clinical Review Published: 31 August 2006; BMJ 333 doi:10.1136/bmj.38922.650521.80
- Letter Published: 25 May 2006; BMJ 332 doi:10.1136/bmj.332.7552.1272-b
- Letter Published: 25 May 2006; BMJ 332 doi:10.1136/bmj.332.7552.1272
- Research Published: 20 March 2008; BMJ 336 doi:10.1136/bmj.39472.580984.AE
See more
- Sixty seconds on . . . 10 000 stepsBMJ March 08, 2024, 384 q598; DOI: https://doi.org/10.1136/bmj.q598
- Scarlett McNally: Enabling active travel can improve the UK’s healthBMJ March 06, 2024, 384 q522; DOI: https://doi.org/10.1136/bmj.q522
- Scarlett McNally: Boosting swimming for health and joyBMJ February 20, 2024, 384 q393; DOI: https://doi.org/10.1136/bmj.q393
- Variability in blood pressure could help predict heart attack and stroke risk, researchers sayBMJ February 09, 2024, 384 q363; DOI: https://doi.org/10.1136/bmj.q363
- Scarlett McNally: Preventing obesity is different from curing it—and even more urgentBMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134
Cited by...
- Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial
- Adherence to the American Diabetes Association standards of care among patients with type 2 diabetes in primary care in Saudi Arabia
- Is diabetes a coronary artery disease equivalent?
- Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
- Awareness, Treatment, and Control of LDL Cholesterol Are Lower Among U.S. Adults With Undiagnosed Diabetes Versus Diagnosed Diabetes
- Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes: Reconciling the Recent Clinical Trial Data
- Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol
- Lipid re-screening: what is the best measure and interval?
- Diabetes and atherosclerosis: is there a role for hyperglycemia?
- CNTO736, a Novel Glucagon-Like Peptide-1 Receptor Agonist, Ameliorates Insulin Resistance and Inhibits Very Low-Density Lipoprotein Production in High-Fat-Fed Mice
- Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue With Lipoprotein Particle Number and Size in Type 2 Diabetes
- Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
- Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
- Should We Prescribe Statin and Aspirin for Every Diabetic Patient?: Is it time for a polypill?
- Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
- The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance
- Essential Role of Insulin and Insulin-Like Growth Factor 1 Receptor Signaling in Cardiac Development and Function
- Prevention and early detection of vascular complications of diabetes
- From the Library
- Statins for primary prevention in type 2 diabetes
- Aggressive Lipid Lowering Is Especially Helpful in Diabetics
- Aggressive Lipid Lowering Is Especially Helpful in Diabetics
- Lipid lowering drugs in diabetes: Abstract was misleading
- Lipid lowering drugs in diabetes: Lipid lowering has ophthalmic benefits
- Lipid lowering drugs in diabetes: Absolute risk reduction is what counts
- Diabetes and lipid lowering: where are we?